ASCO 2017 - Lung Cancer - Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Patients

Video

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Mutation Positive Patients.

Maintenance Alimta in Advanced NSCLC Shows Significant Improvement in Progression-Free Survival

Article

Last year, a provocative trial was presented at ASCO that compared early vs. later taxotere as second line therapy. I described that study here, and it showed a very significant improvement in progression-free survival (PFS) and a near significant improvement in overall survival (OS) for the recipients of taxotere immediately after four cycles of first line chemo for advanced NSCLC.

Subscribe to progression-free survival